Lactococcus lactis KF140 Ameliorates Nonalcoholic Fatty Liver Disease Induced by Nε‐Carboxymethyl‐Lysine and High‐Fat Diet
Scope Long‐term consumption of excessive dietary advanced glycation end‐products such as Nε‐carboxymethyl‐lysine (CML), which are produced by the Maillard reaction during food thermal processing, leads to nonalcoholic fatty liver disease (NAFLD) along with high fat consumption. The study previously...
Gespeichert in:
| Veröffentlicht in: | Molecular nutrition & food research 2024-08, Vol.68 (16), p.e2400260-n/a |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 16 |
| container_start_page | e2400260 |
| container_title | Molecular nutrition & food research |
| container_volume | 68 |
| creator | Lee, Hye‐Bin Park, Miri Lee, So‐Young Ha, Sang Keun Kim, Yoonsook Lee, Kwang‐Won Park, Ho‐Young |
| description | Scope
Long‐term consumption of excessive dietary advanced glycation end‐products such as Nε‐carboxymethyl‐lysine (CML), which are produced by the Maillard reaction during food thermal processing, leads to nonalcoholic fatty liver disease (NAFLD) along with high fat consumption. The study previously finds that administration of Lactococcus lactis KF140 (LL‐KF140) detoxifies CML by decreasing CML absorption both in a rat model and clinical trial.
Methods and results
The present study evaluates the ameliorative effect of LL‐KF140 on NAFLD and fatty liver‐related biomarkers in a mouse model induced by CML and high fat. LL‐KF140 is orally administered to mice at a concentration of 1 × 107 or 1 × 108 colony‐forming unit (CFU) per mouse for 8 weeks. LL‐KF140 administration ameliorates the NAFLD‐related symptoms by reducing body weight and fat mass gain along with levels of serum aspartate transaminase, alanine transferase, and lipids as well as glucose intolerance and insulin resistance in CML‐treated mice. In addition, histological analysis including staining and western blotting shows that LL‐KF140 suppresses the lipogenesis pathway and CML absorption, thereby suppressing CML‐induced NAFLD.
Conclusion
These findings suggest that LL‐KF140 attenuates dietary CML‐induced NAFLD by suppressing the de novo lipogenesis pathway, and it may be used as a probiotic strain.
Lactococcus lactis KF140 (LL‐KF140) attenuates dietary CML‐induced nonalcoholic fatty liver disease by suppressing the de novo lipogenesis pathway, and it may be used as a probiotic strain. |
| doi_str_mv | 10.1002/mnfr.202400260 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153701030</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3153701030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2861-6265fa55fd126259c605a072b830edb82dba97d65aa76135d7ae35919e3d780d3</originalsourceid><addsrcrecordid>eNqFkstu1DAUhi0EoqWwZYksselmpr7ElyyrKUOrhkFCsI4c-4RxlcTFTijZwRvwMrwGD8GT4NGUWbDp6lz0nV865z8IvaRkSQlhZ_3QxiUjrMiFJI_QMZWULwrK-eNDzsQRepbSDSGcsoI_RUdcl5JpUR6jH5WxY7DB2inhLuc-4es1LQg-76HzIZoREt6EwXQ2bEPnLV6bcZxx5b9CxBc-gUmArwY3WXC4mfHm968_33-uTGzCt7mHcTt3ua7m5AfAZnD40n_e5k6WyeMwPkdPWtMleHEfT9Cn9ZuPq8tF9f7t1eq8WlimJV1IJkVrhGgdZZKJ0koiDFGs0ZyAazRzjSmVk8IYldcWThngoqQlcKc0cfwEne51b2P4MkEa694nC11nBghTqjkVXBFKOHkYJUooUkjFMvr6P_QmTDFfa0eVSlNKtcjUck_ZGFKK0Na30fcmzjUl9c7HeudjffAxD7y6l52aHtwB_2dcBoo9cOc7mB-Qq99t1h8Knb_iL7EFqx8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3097811185</pqid></control><display><type>article</type><title>Lactococcus lactis KF140 Ameliorates Nonalcoholic Fatty Liver Disease Induced by Nε‐Carboxymethyl‐Lysine and High‐Fat Diet</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lee, Hye‐Bin ; Park, Miri ; Lee, So‐Young ; Ha, Sang Keun ; Kim, Yoonsook ; Lee, Kwang‐Won ; Park, Ho‐Young</creator><creatorcontrib>Lee, Hye‐Bin ; Park, Miri ; Lee, So‐Young ; Ha, Sang Keun ; Kim, Yoonsook ; Lee, Kwang‐Won ; Park, Ho‐Young</creatorcontrib><description>Scope
Long‐term consumption of excessive dietary advanced glycation end‐products such as Nε‐carboxymethyl‐lysine (CML), which are produced by the Maillard reaction during food thermal processing, leads to nonalcoholic fatty liver disease (NAFLD) along with high fat consumption. The study previously finds that administration of Lactococcus lactis KF140 (LL‐KF140) detoxifies CML by decreasing CML absorption both in a rat model and clinical trial.
Methods and results
The present study evaluates the ameliorative effect of LL‐KF140 on NAFLD and fatty liver‐related biomarkers in a mouse model induced by CML and high fat. LL‐KF140 is orally administered to mice at a concentration of 1 × 107 or 1 × 108 colony‐forming unit (CFU) per mouse for 8 weeks. LL‐KF140 administration ameliorates the NAFLD‐related symptoms by reducing body weight and fat mass gain along with levels of serum aspartate transaminase, alanine transferase, and lipids as well as glucose intolerance and insulin resistance in CML‐treated mice. In addition, histological analysis including staining and western blotting shows that LL‐KF140 suppresses the lipogenesis pathway and CML absorption, thereby suppressing CML‐induced NAFLD.
Conclusion
These findings suggest that LL‐KF140 attenuates dietary CML‐induced NAFLD by suppressing the de novo lipogenesis pathway, and it may be used as a probiotic strain.
Lactococcus lactis KF140 (LL‐KF140) attenuates dietary CML‐induced nonalcoholic fatty liver disease by suppressing the de novo lipogenesis pathway, and it may be used as a probiotic strain.</description><identifier>ISSN: 1613-4125</identifier><identifier>ISSN: 1613-4133</identifier><identifier>EISSN: 1613-4133</identifier><identifier>DOI: 10.1002/mnfr.202400260</identifier><identifier>PMID: 38962859</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Absorption ; advanced glycation end products ; Advanced glycosylation end products ; Alanine ; Alanine Transaminase - blood ; animal models ; Animals ; Aspartate transaminase ; Biomarkers ; blood serum ; Body fat ; Body weight ; Body weight gain ; clinical trials ; Diet, High-Fat - adverse effects ; fat intake ; Fatty liver ; Food consumption ; Food processing ; food research ; glucose ; Glucose tolerance ; High fat diet ; histology ; Insulin Resistance ; Lactococcus lactis ; Lipids ; Lipogenesis ; Lipogenesis - drug effects ; Liver ; Liver - drug effects ; Liver - metabolism ; Liver diseases ; Lysine ; Lysine - analogs & derivatives ; Lysine - pharmacology ; Maillard reaction ; Male ; Mice ; Mice, Inbred C57BL ; Non-alcoholic Fatty Liver Disease - drug therapy ; Non-alcoholic Fatty Liver Disease - etiology ; nonalcoholic fatty liver disease ; Nε‐carboxymethyl‐lysine ; Oral administration ; Probiotics ; Probiotics - pharmacology ; Transaminase ; Western blotting</subject><ispartof>Molecular nutrition & food research, 2024-08, Vol.68 (16), p.e2400260-n/a</ispartof><rights>2024 The Author(s). Molecular Nutrition & Food Research published by Wiley‐VCH GmbH</rights><rights>2024 The Author(s). Molecular Nutrition & Food Research published by Wiley‐VCH GmbH.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2861-6265fa55fd126259c605a072b830edb82dba97d65aa76135d7ae35919e3d780d3</cites><orcidid>0000-0002-3329-2279 ; 0000-0002-9966-9059</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmnfr.202400260$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmnfr.202400260$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38962859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Hye‐Bin</creatorcontrib><creatorcontrib>Park, Miri</creatorcontrib><creatorcontrib>Lee, So‐Young</creatorcontrib><creatorcontrib>Ha, Sang Keun</creatorcontrib><creatorcontrib>Kim, Yoonsook</creatorcontrib><creatorcontrib>Lee, Kwang‐Won</creatorcontrib><creatorcontrib>Park, Ho‐Young</creatorcontrib><title>Lactococcus lactis KF140 Ameliorates Nonalcoholic Fatty Liver Disease Induced by Nε‐Carboxymethyl‐Lysine and High‐Fat Diet</title><title>Molecular nutrition & food research</title><addtitle>Mol Nutr Food Res</addtitle><description>Scope
Long‐term consumption of excessive dietary advanced glycation end‐products such as Nε‐carboxymethyl‐lysine (CML), which are produced by the Maillard reaction during food thermal processing, leads to nonalcoholic fatty liver disease (NAFLD) along with high fat consumption. The study previously finds that administration of Lactococcus lactis KF140 (LL‐KF140) detoxifies CML by decreasing CML absorption both in a rat model and clinical trial.
Methods and results
The present study evaluates the ameliorative effect of LL‐KF140 on NAFLD and fatty liver‐related biomarkers in a mouse model induced by CML and high fat. LL‐KF140 is orally administered to mice at a concentration of 1 × 107 or 1 × 108 colony‐forming unit (CFU) per mouse for 8 weeks. LL‐KF140 administration ameliorates the NAFLD‐related symptoms by reducing body weight and fat mass gain along with levels of serum aspartate transaminase, alanine transferase, and lipids as well as glucose intolerance and insulin resistance in CML‐treated mice. In addition, histological analysis including staining and western blotting shows that LL‐KF140 suppresses the lipogenesis pathway and CML absorption, thereby suppressing CML‐induced NAFLD.
Conclusion
These findings suggest that LL‐KF140 attenuates dietary CML‐induced NAFLD by suppressing the de novo lipogenesis pathway, and it may be used as a probiotic strain.
Lactococcus lactis KF140 (LL‐KF140) attenuates dietary CML‐induced nonalcoholic fatty liver disease by suppressing the de novo lipogenesis pathway, and it may be used as a probiotic strain.</description><subject>Absorption</subject><subject>advanced glycation end products</subject><subject>Advanced glycosylation end products</subject><subject>Alanine</subject><subject>Alanine Transaminase - blood</subject><subject>animal models</subject><subject>Animals</subject><subject>Aspartate transaminase</subject><subject>Biomarkers</subject><subject>blood serum</subject><subject>Body fat</subject><subject>Body weight</subject><subject>Body weight gain</subject><subject>clinical trials</subject><subject>Diet, High-Fat - adverse effects</subject><subject>fat intake</subject><subject>Fatty liver</subject><subject>Food consumption</subject><subject>Food processing</subject><subject>food research</subject><subject>glucose</subject><subject>Glucose tolerance</subject><subject>High fat diet</subject><subject>histology</subject><subject>Insulin Resistance</subject><subject>Lactococcus lactis</subject><subject>Lipids</subject><subject>Lipogenesis</subject><subject>Lipogenesis - drug effects</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Liver diseases</subject><subject>Lysine</subject><subject>Lysine - analogs & derivatives</subject><subject>Lysine - pharmacology</subject><subject>Maillard reaction</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Non-alcoholic Fatty Liver Disease - drug therapy</subject><subject>Non-alcoholic Fatty Liver Disease - etiology</subject><subject>nonalcoholic fatty liver disease</subject><subject>Nε‐carboxymethyl‐lysine</subject><subject>Oral administration</subject><subject>Probiotics</subject><subject>Probiotics - pharmacology</subject><subject>Transaminase</subject><subject>Western blotting</subject><issn>1613-4125</issn><issn>1613-4133</issn><issn>1613-4133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNqFkstu1DAUhi0EoqWwZYksselmpr7ElyyrKUOrhkFCsI4c-4RxlcTFTijZwRvwMrwGD8GT4NGUWbDp6lz0nV865z8IvaRkSQlhZ_3QxiUjrMiFJI_QMZWULwrK-eNDzsQRepbSDSGcsoI_RUdcl5JpUR6jH5WxY7DB2inhLuc-4es1LQg-76HzIZoREt6EwXQ2bEPnLV6bcZxx5b9CxBc-gUmArwY3WXC4mfHm968_33-uTGzCt7mHcTt3ua7m5AfAZnD40n_e5k6WyeMwPkdPWtMleHEfT9Cn9ZuPq8tF9f7t1eq8WlimJV1IJkVrhGgdZZKJ0koiDFGs0ZyAazRzjSmVk8IYldcWThngoqQlcKc0cfwEne51b2P4MkEa694nC11nBghTqjkVXBFKOHkYJUooUkjFMvr6P_QmTDFfa0eVSlNKtcjUck_ZGFKK0Na30fcmzjUl9c7HeudjffAxD7y6l52aHtwB_2dcBoo9cOc7mB-Qq99t1h8Knb_iL7EFqx8</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Lee, Hye‐Bin</creator><creator>Park, Miri</creator><creator>Lee, So‐Young</creator><creator>Ha, Sang Keun</creator><creator>Kim, Yoonsook</creator><creator>Lee, Kwang‐Won</creator><creator>Park, Ho‐Young</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0002-3329-2279</orcidid><orcidid>https://orcid.org/0000-0002-9966-9059</orcidid></search><sort><creationdate>202408</creationdate><title>Lactococcus lactis KF140 Ameliorates Nonalcoholic Fatty Liver Disease Induced by Nε‐Carboxymethyl‐Lysine and High‐Fat Diet</title><author>Lee, Hye‐Bin ; Park, Miri ; Lee, So‐Young ; Ha, Sang Keun ; Kim, Yoonsook ; Lee, Kwang‐Won ; Park, Ho‐Young</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2861-6265fa55fd126259c605a072b830edb82dba97d65aa76135d7ae35919e3d780d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Absorption</topic><topic>advanced glycation end products</topic><topic>Advanced glycosylation end products</topic><topic>Alanine</topic><topic>Alanine Transaminase - blood</topic><topic>animal models</topic><topic>Animals</topic><topic>Aspartate transaminase</topic><topic>Biomarkers</topic><topic>blood serum</topic><topic>Body fat</topic><topic>Body weight</topic><topic>Body weight gain</topic><topic>clinical trials</topic><topic>Diet, High-Fat - adverse effects</topic><topic>fat intake</topic><topic>Fatty liver</topic><topic>Food consumption</topic><topic>Food processing</topic><topic>food research</topic><topic>glucose</topic><topic>Glucose tolerance</topic><topic>High fat diet</topic><topic>histology</topic><topic>Insulin Resistance</topic><topic>Lactococcus lactis</topic><topic>Lipids</topic><topic>Lipogenesis</topic><topic>Lipogenesis - drug effects</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Liver diseases</topic><topic>Lysine</topic><topic>Lysine - analogs & derivatives</topic><topic>Lysine - pharmacology</topic><topic>Maillard reaction</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Non-alcoholic Fatty Liver Disease - drug therapy</topic><topic>Non-alcoholic Fatty Liver Disease - etiology</topic><topic>nonalcoholic fatty liver disease</topic><topic>Nε‐carboxymethyl‐lysine</topic><topic>Oral administration</topic><topic>Probiotics</topic><topic>Probiotics - pharmacology</topic><topic>Transaminase</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Hye‐Bin</creatorcontrib><creatorcontrib>Park, Miri</creatorcontrib><creatorcontrib>Lee, So‐Young</creatorcontrib><creatorcontrib>Ha, Sang Keun</creatorcontrib><creatorcontrib>Kim, Yoonsook</creatorcontrib><creatorcontrib>Lee, Kwang‐Won</creatorcontrib><creatorcontrib>Park, Ho‐Young</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Molecular nutrition & food research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Hye‐Bin</au><au>Park, Miri</au><au>Lee, So‐Young</au><au>Ha, Sang Keun</au><au>Kim, Yoonsook</au><au>Lee, Kwang‐Won</au><au>Park, Ho‐Young</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lactococcus lactis KF140 Ameliorates Nonalcoholic Fatty Liver Disease Induced by Nε‐Carboxymethyl‐Lysine and High‐Fat Diet</atitle><jtitle>Molecular nutrition & food research</jtitle><addtitle>Mol Nutr Food Res</addtitle><date>2024-08</date><risdate>2024</risdate><volume>68</volume><issue>16</issue><spage>e2400260</spage><epage>n/a</epage><pages>e2400260-n/a</pages><issn>1613-4125</issn><issn>1613-4133</issn><eissn>1613-4133</eissn><abstract>Scope
Long‐term consumption of excessive dietary advanced glycation end‐products such as Nε‐carboxymethyl‐lysine (CML), which are produced by the Maillard reaction during food thermal processing, leads to nonalcoholic fatty liver disease (NAFLD) along with high fat consumption. The study previously finds that administration of Lactococcus lactis KF140 (LL‐KF140) detoxifies CML by decreasing CML absorption both in a rat model and clinical trial.
Methods and results
The present study evaluates the ameliorative effect of LL‐KF140 on NAFLD and fatty liver‐related biomarkers in a mouse model induced by CML and high fat. LL‐KF140 is orally administered to mice at a concentration of 1 × 107 or 1 × 108 colony‐forming unit (CFU) per mouse for 8 weeks. LL‐KF140 administration ameliorates the NAFLD‐related symptoms by reducing body weight and fat mass gain along with levels of serum aspartate transaminase, alanine transferase, and lipids as well as glucose intolerance and insulin resistance in CML‐treated mice. In addition, histological analysis including staining and western blotting shows that LL‐KF140 suppresses the lipogenesis pathway and CML absorption, thereby suppressing CML‐induced NAFLD.
Conclusion
These findings suggest that LL‐KF140 attenuates dietary CML‐induced NAFLD by suppressing the de novo lipogenesis pathway, and it may be used as a probiotic strain.
Lactococcus lactis KF140 (LL‐KF140) attenuates dietary CML‐induced nonalcoholic fatty liver disease by suppressing the de novo lipogenesis pathway, and it may be used as a probiotic strain.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38962859</pmid><doi>10.1002/mnfr.202400260</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3329-2279</orcidid><orcidid>https://orcid.org/0000-0002-9966-9059</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1613-4125 |
| ispartof | Molecular nutrition & food research, 2024-08, Vol.68 (16), p.e2400260-n/a |
| issn | 1613-4125 1613-4133 1613-4133 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3153701030 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Absorption advanced glycation end products Advanced glycosylation end products Alanine Alanine Transaminase - blood animal models Animals Aspartate transaminase Biomarkers blood serum Body fat Body weight Body weight gain clinical trials Diet, High-Fat - adverse effects fat intake Fatty liver Food consumption Food processing food research glucose Glucose tolerance High fat diet histology Insulin Resistance Lactococcus lactis Lipids Lipogenesis Lipogenesis - drug effects Liver Liver - drug effects Liver - metabolism Liver diseases Lysine Lysine - analogs & derivatives Lysine - pharmacology Maillard reaction Male Mice Mice, Inbred C57BL Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - etiology nonalcoholic fatty liver disease Nε‐carboxymethyl‐lysine Oral administration Probiotics Probiotics - pharmacology Transaminase Western blotting |
| title | Lactococcus lactis KF140 Ameliorates Nonalcoholic Fatty Liver Disease Induced by Nε‐Carboxymethyl‐Lysine and High‐Fat Diet |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T09%3A02%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lactococcus%20lactis%20KF140%20Ameliorates%20Nonalcoholic%20Fatty%20Liver%20Disease%20Induced%20by%20N%CE%B5%E2%80%90Carboxymethyl%E2%80%90Lysine%20and%20High%E2%80%90Fat%20Diet&rft.jtitle=Molecular%20nutrition%20&%20food%20research&rft.au=Lee,%20Hye%E2%80%90Bin&rft.date=2024-08&rft.volume=68&rft.issue=16&rft.spage=e2400260&rft.epage=n/a&rft.pages=e2400260-n/a&rft.issn=1613-4125&rft.eissn=1613-4133&rft_id=info:doi/10.1002/mnfr.202400260&rft_dat=%3Cproquest_cross%3E3153701030%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3097811185&rft_id=info:pmid/38962859&rfr_iscdi=true |